The recent acquisitions by pharmaceutical giants Johnson & Johnson and Bristol Myers Squibb, worth a combined $28billion, ...

The following is a summary of “Intranasal racemic ketamine maintenance therapy for patients with treatment-resistant depression: a naturalistic feasibility study,” published in the January 2025 issue ...

The company’s lead drug candidate utilizing WaferiX is Wafermine, the world’s first patented sublingual racemic ketamine wafer for the treatment of acute moderate to severe pain and major ...

The original form of ketamine, formally known as "racemic" ketamine, is composed of two mirror-image molecules or enantiomers, known as S(+)-ketamine and R(–)-ketamine. S(+) and R(–) forms of ...

Elizabeth began receiving racemic ketamine treatments once per week, in the fall of 2022, and though she was making considerable progress, she believed more was possible. She then requested that ...

It develops AWKN-001, a novel medication-assisted treatments (MAT) consisting of racemic ketamine, delivered intravenously, and manualized relapse prevention cognitive behavioural therapy (CBT ...

to supply intranasal racemic ketamine (SLS-002) for the Department of Defense’s Military and Veterans Adaptative Platform ...